NO980630L - Kjemiske forbindelser - Google Patents
Kjemiske forbindelserInfo
- Publication number
- NO980630L NO980630L NO980630A NO980630A NO980630L NO 980630 L NO980630 L NO 980630L NO 980630 A NO980630 A NO 980630A NO 980630 A NO980630 A NO 980630A NO 980630 L NO980630 L NO 980630L
- Authority
- NO
- Norway
- Prior art keywords
- enzyme
- cpb
- mutated
- adept
- prodrug
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 abstract 5
- 108090000790 Enzymes Proteins 0.000 abstract 5
- 102000003670 Carboxypeptidase B Human genes 0.000 abstract 4
- 108090000087 Carboxypeptidase B Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9516810.0A GB9516810D0 (en) | 1995-08-16 | 1995-08-16 | Chemical compounds |
| GBGB9611019.2A GB9611019D0 (en) | 1996-05-25 | 1996-05-25 | Chemical compounds |
| GBGB9612295.7A GB9612295D0 (en) | 1996-06-12 | 1996-06-12 | Chemical compounds |
| PCT/GB1996/001975 WO1997007769A2 (en) | 1995-08-16 | 1996-08-13 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO980630D0 NO980630D0 (no) | 1998-02-13 |
| NO980630L true NO980630L (no) | 1998-04-07 |
Family
ID=27267862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO980630A NO980630L (no) | 1995-08-16 | 1998-02-13 | Kjemiske forbindelser |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6436691B1 (cs) |
| EP (1) | EP0844885A2 (cs) |
| JP (1) | JPH11511970A (cs) |
| KR (1) | KR19990036383A (cs) |
| CN (1) | CN1193278A (cs) |
| AU (1) | AU707689B2 (cs) |
| BR (1) | BR9610050A (cs) |
| CA (1) | CA2227040A1 (cs) |
| CZ (1) | CZ43098A3 (cs) |
| GB (1) | GB2317387B (cs) |
| HU (1) | HUP9900062A3 (cs) |
| IL (1) | IL123271A0 (cs) |
| MX (1) | MX9800967A (cs) |
| NO (1) | NO980630L (cs) |
| NZ (1) | NZ315713A (cs) |
| PL (1) | PL325017A1 (cs) |
| SK (1) | SK19498A3 (cs) |
| TR (1) | TR199800233T1 (cs) |
| WO (1) | WO1997007769A2 (cs) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2227040A1 (en) | 1995-08-16 | 1997-03-06 | Zeneca Limited | Chemical compounds |
| GB9703201D0 (en) * | 1997-02-15 | 1997-04-02 | Zeneca Ltd | Chemical compounds |
| GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| CA2355402A1 (en) * | 1998-12-21 | 2000-06-29 | Eli Lilly And Company | Recombinant synthesis of beta-lipotropin and other peptides |
| JP2003509040A (ja) * | 1999-09-17 | 2003-03-11 | ジェンジム トランスジェニックス コーポレイション | 遺伝子導入により産生された融合タンパク質 |
| ATE517181T1 (de) * | 2004-09-27 | 2011-08-15 | Sanofi Aventis Deutschland | Rekombinante carboxypeptidase b |
| EP2318544A2 (en) * | 2008-07-14 | 2011-05-11 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Method for predicting and detecting tumor metastasis |
| ES2595364T3 (es) * | 2008-10-07 | 2016-12-29 | The Regents Of The University Of California | Producción de proteínas NELL recombinantes |
| JP7574821B2 (ja) * | 2022-03-29 | 2024-10-29 | 横河電機株式会社 | 複合体の製造方法、微生物の混入の有無を判別する方法及び、混入した微生物の同定を行う方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4364934A (en) | 1979-12-04 | 1982-12-21 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human early thymocyte antigen and methods for preparing same |
| HU190129B (en) * | 1983-07-11 | 1986-08-28 | Reanal Finomvegyszergyar,Hu | Process for the isolation of carboxypeptidase b enzyme from mammal pancreas |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| GB8809616D0 (en) | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
| US5632990A (en) | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
| US5433955A (en) | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
| DK0454783T3 (da) | 1989-01-23 | 1995-10-16 | Akzo Nobel Nv | Sted-specifik in vivo aktivering af terapeutiske lægemidler |
| US5206161A (en) * | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| WO1993015208A1 (en) | 1992-01-30 | 1993-08-05 | Genzyme Limited | Chiral synthesis with modified enzymes |
| US6187579B1 (en) * | 1993-10-28 | 2001-02-13 | Carlsberg A/S | Customized proteases |
| GB9323429D0 (en) * | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
| US5389537A (en) | 1994-01-21 | 1995-02-14 | Wisconsin Alumni Research Foundation | Nuclease having altered specificity |
| SK80997A3 (en) * | 1994-12-23 | 1998-02-04 | Zeneca Ltd | Pharmaceutical composition containing an enzymatic component being specific for the target cells |
| IL116696A (en) * | 1995-01-25 | 1999-08-17 | Bio Technology General Corp | Production of enzymatically active recombinant carboxypeptidase b |
| US5837516A (en) * | 1995-03-03 | 1998-11-17 | Genentech, Inc. | Subtilisin variants capable of cleaving substrates containing basic residues |
| CA2227040A1 (en) | 1995-08-16 | 1997-03-06 | Zeneca Limited | Chemical compounds |
| US5985627A (en) * | 1997-02-28 | 1999-11-16 | Carlsberg Laboratory | Modified carboxypeptidase |
-
1996
- 1996-08-13 CA CA002227040A patent/CA2227040A1/en not_active Abandoned
- 1996-08-13 HU HU9900062A patent/HUP9900062A3/hu unknown
- 1996-08-13 KR KR1019980701052A patent/KR19990036383A/ko not_active Withdrawn
- 1996-08-13 PL PL96325017A patent/PL325017A1/xx unknown
- 1996-08-13 WO PCT/GB1996/001975 patent/WO1997007769A2/en not_active Ceased
- 1996-08-13 IL IL12327196A patent/IL123271A0/xx unknown
- 1996-08-13 NZ NZ315713A patent/NZ315713A/xx unknown
- 1996-08-13 CN CN96196288A patent/CN1193278A/zh active Pending
- 1996-08-13 CZ CZ98430A patent/CZ43098A3/cs unknown
- 1996-08-13 AU AU67476/96A patent/AU707689B2/en not_active Ceased
- 1996-08-13 JP JP9509938A patent/JPH11511970A/ja active Pending
- 1996-08-13 EP EP96927772A patent/EP0844885A2/en not_active Withdrawn
- 1996-08-13 SK SK194-98A patent/SK19498A3/sk unknown
- 1996-08-13 US US09/011,769 patent/US6436691B1/en not_active Expired - Fee Related
- 1996-08-13 BR BR9610050-8A patent/BR9610050A/pt not_active Application Discontinuation
- 1996-08-13 GB GB9726893A patent/GB2317387B/en not_active Expired - Fee Related
- 1996-08-13 TR TR1998/00233T patent/TR199800233T1/xx unknown
-
1998
- 1998-02-03 MX MX9800967A patent/MX9800967A/es unknown
- 1998-02-13 NO NO980630A patent/NO980630L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX9800967A (es) | 1998-11-29 |
| HUP9900062A2 (hu) | 1999-04-28 |
| AU6747696A (en) | 1997-03-19 |
| BR9610050A (pt) | 1999-10-13 |
| KR19990036383A (ko) | 1999-05-25 |
| CZ43098A3 (cs) | 1998-05-13 |
| WO1997007769A2 (en) | 1997-03-06 |
| AU707689B2 (en) | 1999-07-15 |
| GB2317387A (en) | 1998-03-25 |
| IL123271A0 (en) | 1998-09-24 |
| GB9726893D0 (en) | 1998-02-18 |
| HUP9900062A3 (en) | 1999-11-29 |
| CA2227040A1 (en) | 1997-03-06 |
| SK19498A3 (en) | 1998-09-09 |
| CN1193278A (zh) | 1998-09-16 |
| PL325017A1 (en) | 1998-07-06 |
| TR199800233T1 (xx) | 1998-06-22 |
| GB2317387B (en) | 1999-08-18 |
| US6436691B1 (en) | 2002-08-20 |
| NO980630D0 (no) | 1998-02-13 |
| EP0844885A2 (en) | 1998-06-03 |
| WO1997007769A3 (en) | 1997-07-10 |
| JPH11511970A (ja) | 1999-10-19 |
| NZ315713A (en) | 1999-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68928466D1 (de) | Verbesserungen an Abgabesystemen für Arzneimittel | |
| NO990518D0 (no) | Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse | |
| DE69636923D1 (de) | Katalytischer antikörper gegen aldolase | |
| NO980630L (no) | Kjemiske forbindelser | |
| MY108519A (en) | Novel antibodies reactive with human carcinomas. | |
| IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
| AUPN568095A0 (en) | Anti-Galalpha(1,3)Gal antibody binding peptides | |
| WO2008089053A3 (en) | Gp100-specific t cell receptors and related materials and methods of use | |
| AU639241B2 (en) | Bispecific and oligospecific mono- and oligovalent receptors, the preparation and use thereof | |
| DK1383785T3 (da) | Rekombinant tumorspecifikt antistof og anvendelse deraf | |
| DE59109161D1 (de) | Neue treibgase und ihre verwendung in arzneimittelzubereitungen | |
| TNSN93012A1 (fr) | Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine | |
| WO2020132366A4 (en) | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof | |
| WO2023137156A3 (en) | T cell modulatory polypeptides with conjugation sites and methods of use thereof | |
| Simpson et al. | Killing of cultured hepatocytes by conjugates of asialofetuin and EGF linked to the A chains of ricin or diphtheria toxin | |
| WO1993004191A1 (en) | Noncytolytic toxin conjugates | |
| EP1116791A4 (en) | NEW TUMOR-ANTIGEN-PROTEIN SART-3 AND TUMOR-ANTIGEN-PEPTID OF IT | |
| CA2124217A1 (en) | Inactivation of cytotoxic drugs | |
| AU5698996A (en) | Transepithelial transport of molecular species | |
| WO2022183112A3 (en) | Compositions and methods comprising antibodies that bind to covalent peptide conjugates | |
| DE60043070D1 (de) | Proteine-abgabe durch polare epithelzellen schichte | |
| NO972522L (no) | Monoklonale antistoffer med immunoundertrykkende aktivitet | |
| EP0453097A3 (en) | Zusammensetzung enthaltend zumindest zwei verschiedene Antikörper oder deren Fragmente | |
| Marsh et al. | A flexible peptide spacer increases the efficacy of holoricin anti-T cell immunotoxins. | |
| AU2003270010A1 (en) | Transferrin fusion protein libraries |